GR1803 injection Clinical Trials
3 recruitingDrug
Phase 22Phase 31Phase 11
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.358 enrolled1 locationNCT07452198
Recruiting
Phase 1Phase 2
A Study of GR1803 in Systemic Lupus Erythematosus
Systemic Lupus ErthematosusAuto Immune Disease
Genrix (Shanghai) Biopharmaceutical Co., Ltd.44 enrolled1 locationNCT07348055
Recruiting
Phase 2
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.116 enrolled1 locationNCT06566547